{"ticker": {"uuid": "c0833403-7ce0-4f45-9fcb-f113fac0ca76", "symbol": "MGX", "name": "Metagenomi, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Metagenomi Therapeutics (MGX) Edges Higher as Stock Tests Key Resistance Near $1.41 - Small Cap Breakouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMWRSNGhNeVdsWXJqeE1xdmxVQl9sTjR4ZFVLS3dOR0VwQ1hjLWFGLVRqTzlwRTd4QnNDZlkzaWNjNVhmaWUzcWo3RnlnZ0NhNUktNmR0VS1Gem5SbDVQcnd6TS1aZHN2QkhHR1FlRjRTR3ZNcXd0Qndod2VjX0Zzbl9qUWY1TE5xTklrUUhqWjIzNFVGRkFqWW10REFEeWFJdUduQW5rVjJmRmxZcmU5bk9KUWZzS0swSzRWYkp3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T17:33:34+00:00", "published_display": "14 Jul 2026 17:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential", "summary": "Chardan has initiated coverage on Metagenomi Inc (NASDAQ:MGX) with a buy rating and a $5.00 price target, citing the potential of its lead asset, MGX-001, as a one-time curative treatment for Hemophilia A. The firm believes MGX-001's proprietary gene editing approach is superior ", "url": "https://ng.investing.com/news/stock-market-news/chardan-initiates-metagenomi-stock-with-buy-5-target-on-gene-therapy-potential-93CH-2588641", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T06:40:15", "published_display": "08 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Cuts Price Target on Metagenomi to $5 From $7, Keeps Buy Rating", "summary": "Chardan has revised its price target for Metagenomi (MGX) down to $5 from $7, while maintaining a Buy rating on the stock. This adjustment comes despite the retained positive outlook from the analyst firm. Investors should note this change in valuation target.", "url": "https://www.moomoo.com/news/post/72584690/chardan-cuts-price-target-on-metagenomi-to-5-from-7?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T17:41:34", "published_display": "07 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit", "summary": "Rosen Law Firm reminds investors who purchased Metagenomi, Inc. (NASDAQ: MGX) stock during its IPO between February 9-13, 2024, of the November 25, 2024, lead plaintiff deadline for a class action lawsuit. The lawsuit alleges that Metagenomi misrepresented its relationship with M", "url": "https://www.gurufocus.com/news/2601404/mgx-deadline-mgx-investors-have-opportunity-to-lead-metagenomi-inc-securities-lawsuit?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-06T18:40:19", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Metagenomi Therapeutics, Inc. (MGX) stock, including analyst opinions, historical performance data, and key financial metrics. It highlights that analysts project a maximum price of $9.00 and a minimum of $5.00 for MGX, while ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:49", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "This article focuses on the \"Price to earnings forward\" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It is a financial data point presented within the context of TradingView's platform, indicating a specific financial valuation for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:08", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "The article indicates the \"Price to book forward\" for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It provides basic financial information and market data for the company on TradingView. The content appears to be a stub or a section of a larger financial data page rather than a f", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:18", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "This article provides the \"Price to sales forward\" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, alongside standard disclaimers from data providers like ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:48", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX)", "summary": "This article provides an overview of Metagenomi Therapeutics, Inc. (NASDAQ: MGX) stock performance, analyst forecasts, and key financial data. It covers the current stock price, historical highs and lows, volatility, earnings per share, revenue, net income, and upcoming earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:27", "published_display": "26 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Inc (MGX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed overview of Metagenomi Inc (MGX) stock, focusing on its dividend and stock split history, which currently shows no data for either. It includes current stock performance metrics such as market cap and price changes. The page also features an overvi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mgx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:29", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares", "summary": "Metagenomi Therapeutics (MGX) director Dere Willard H was granted stock options for 21,000 shares of common stock. The options have an exercise price of $1.23 per share and will expire on June 8, 2036. These options will vest fully on the earlier of one year from the grant date o", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-1ae26ccc5773.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:35", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23", "summary": "Metagenomi Therapeutics (MGX) director Reid Laurence was granted 17,400 stock options with an exercise price of $1.23 per share, expiring on June 8, 2036. These options will vest on the earlier of one year from the grant date or the company\u2019s 2027 annual stockholder meeting, cont", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-c648aa8371f9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:35", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23", "summary": "Metagenomi Therapeutics director Eric Bjerkholt was granted stock options for 21,000 shares of common stock at an exercise price of $1.23 per share. These options will vest and become exercisable on the earlier of one year from the grant date or the company's 2027 annual meeting ", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-3531ad7ada72.html", "source_name": "Stock Titan", "published_at": "2026-06-11T17:49:03", "published_display": "11 Jun 2026 17:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike", "summary": "Metagenomi Therapeutics, Inc. director Juergen Eckhardt was granted 21,000 stock options with an exercise price of $1.23 per share and an expiration date of June 8, 2036. The options will vest either on the one-year anniversary of the grant date or the company's 2027 annual meeti", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-96abf9892996.html", "source_name": "Stock Titan", "published_at": "2026-06-11T17:38:03", "published_display": "11 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CEO Jian Irish sells $4,854 in company stock", "summary": "Metagenomi's CEO, Jian Irish, sold 3,737 shares of the company's common stock amounting to $4,854. This transaction was an automatic sale to cover tax withholding obligations related to restricted stock units rather than a discretionary trade. Following the sale, Ms. Irish direct", "url": "https://m.uk.investing.com/news/insider-trading-news/metagenomi-ceo-jian-irish-sells-4854-in-company-stock-93CH-4722247?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T19:10:09", "published_display": "10 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CFO Pamela Wapnick sells $3,746 of company stock", "summary": "Metagenomi CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 on June 5, 2026, to satisfy tax withholding obligations related to vested restricted stock units. This was not a volitional trade, and she now directly owns 208,491 shares. The company's s", "url": "https://m.uk.investing.com/news/insider-trading-news/metagenomi-cfo-pamela-wapnick-sells-3746-of-company-stock-93CH-4722234?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T19:10:09", "published_display": "10 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com", "summary": "Metagenomi Therapeutics, Inc. CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 due to tax withholding obligations upon the vesting of restricted stock units. This transaction was not a volitional trade. The company's stock, NASDAQ:MGX, is trading n", "url": "https://ng.investing.com/news/insider-trading-news/metagenomi-cfo-pamela-wapnick-sells-3746-of-company-stock-93CH-2552402", "source_name": "Investing.com Nigeria", "published_at": "2026-06-10T18:11:03", "published_display": "10 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CEO Jian Irish sells $4,854 in company stock By Investing.com", "summary": "Metagenomi CEO Jian Irish sold 3,737 shares of Metagenomi Therapeutics (NASDAQ:MGX) common stock for $4,854 to cover tax withholding obligations related to restricted stock units. This was an automatic, non-discretionary transaction. Following the sale, Ms. Irish directly holds 3", "url": "https://au.investing.com/news/insider-trading-news/metagenomi-ceo-jian-irish-sells-4854-in-company-stock-93CH-4480994", "source_name": "Investing.com Australia", "published_at": "2026-06-10T17:30:39", "published_display": "10 Jun 2026 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVTS Stock Surges as NVIDIA MGX Tests Revenue Reality", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1lVmJwRlFsT2Z2TmdEYUxjVThfMHpmekxyaE5ZZmlBc2RQbFFkRXIzRmd4WVVNSS1lM01NOWE3Qzl4NG1jR0lkVmp3MnF4bTlJYkliSEZjNExSUklhb2pydjYydU5USzdfU3poYllaZUJSZw?oc=5", "source_name": "EBC Financial Group", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rainmaker NVIDIA has another AI Infrastructure Stock (NASDAQ:NVTS) Soar on News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNb1RMUEpfVUI0eEJoTzhkajgxMW96LW40YTNETVhNWG1uUXh3SUxoTExIM0JhZ1FCRGNDMjd3azlzeU43a2Q0SnNmOUUxR1lONHBfYWdYTHgwenlzdy1uX0NOdEY0OTNHQV9STEw3QVp5QzRYV1FYWWd0b3pFNVNHOGhlZ1MxZ29PdnFjd25ObFp3SVV2LWx0NklIMGhGOWl0S21EbzZSczA?oc=5", "source_name": "Investorideas.com", "published_at": "2026-06-03T16:59:00+00:00", "published_display": "03 Jun 2026 16:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVTS stock surges on NVIDIA MGX collaboration for 800V AI infrastructure", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQM2d4NUVvWWNfWTdZQS0xWkVCdTJRLWZnT0lnMGFwTnRudUUzdkY3YzAxbElzSUV3cTI4SVlyV3dUWmgxaEJ5R3U4NjJOT1dqel9RbHItNUlhWGJHeEwxT3RDcklIeHc1NkNfY0NjVDlfYnlEa2swRXVNRXE5VkdrTWtZbXE5RlRGLU5YTTFPSDdXTlAxcXlDd2ptclhkLUlhazdJ?oc=5", "source_name": "eciks.org", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Navitas Stock Surges 23% on Nvidia AI Partnership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNYW9pRTdwMXN3bHdNR1ZWSDdGWXBJN1FzMUExM2JOS0RQT1UxMWFQYm92Nk9uUENIUXVSMjEydWh2OVc2NFctelVKa3VNLVVwRGwxVkMweXFyU0hTalVrakVMYlpLSzFTZnN3WmpPMGNCYmx0WjJMOXl4cmVUUXQ4aG52Z0JjV1NuZVE?oc=5", "source_name": "Barron's", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia MGX news makes Navitas stock more expensive than SpaceX at $1.7 trillion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaGY5Z2RjeTJXNUw1SXpoWW41ZHZCUjBpUWUwaUFra2lLSXU1SmZTQ3oyZ29xY3Vmb3E2d09NZjBjNU5femNSUEhtZWRaZEZWcE02M1hFNE1Zd2F6bmFJdnJyRHF4SXdCamFKak5malh5WHpzQkdlRmtHUk5iaDZWSkdKczNPUk51VDluSDdQLVNKWk9nOWhvZ2tkcXlJVF93cTJuYXQtbnczUQ?oc=5", "source_name": "Invezz", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPVVJkV0pacXBoUkV0eTdLcWlJcUhFR2ZDODg0VkR6RWQtajJhRmdTVEpyWU1SMlpaSXJMb2RXSmZvamx5al9RcWhwSVRBREhYbHc1ajFqQ0Q1UWdXemhsa1JMTUFpdUV1Z1RvOHRNNlNWVTRsLTktZUtSY190NjJ5dExISUpCM25aV2xweW1lSGlSUUlMMUtla3U3VzRiaTNvYURTaVpR?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNNjl2Ym1UWGZIV2EyeVVrMnotQXd6WHF3Z2t0UURBdm1LWUNNcDdoMHFMNS1QQUxrTlNxVWFtdmlFSVZaTTNCQkNjUC1BOHNzUlNYZzJIZ3ZmYURyb1ZVOGNHVERJREdjV3lySThnT084ZUhoVnNJdzhkTS1RUWF1S1E0ZEVkZzBVN3lpeEV3?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle stock jumps 7% as cloud provider joins investor group to run TikTok's U.S. business", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE83a0c4UkFnOHpsTzRRdkZ5OFA0RDZtVC0yNUpHbEtJMzVFclg3Q2V3bk9sS1dzbXhCeHFHdkxwZHJTSDJJSUx4ckxGSlVjR1I1U2NKY0dmTkhmem5nX3lmaHRZTW16dDloWHNxNU9jZWRDZGY5ZUd5d1ZOMNIBgAFBVV95cUxNQnhyekllQ3ZjbE5kYmRVODctb1ZBeXphV21YTDYtTzhZTmloTzc1UGdaYlhvVWFraEU1RjFJcEZsWVFyRlliYVhkbmRwOUxkVzJxRmNhU2d1X0Zrblpad3BTRWRrekUwZ0tRZWszcUdZQVdmMXFzdzFFRk5TcHhXOQ?oc=5", "source_name": "CNBC", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle Stock Jumps After Forming TikTok Joint Venture", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYnhKQTJmc19GNmdVNlF0VjdmMkZ6S21mQ2l0cExGRmN2Y0ZQR2F5d040UjhSRW5QTVl0TmlCbzBUanRuSW11Tjk2czZqVy1ldEFPWlRhdS1ZS0FINFJXWlUwU1JKNUg4RDJFQngya1pxbDVBNVl0X29lanlDb1VVb2V4UGgwZDJS?oc=5", "source_name": "Barron's", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNWWdIaG8zemNob2FuRVhJMG9sWVpMSl9NbkdyMVVpOXUtR0NJS2ZrTDFmc3RldHZaOURUU0VfNG1jeEtmeXdjSVhHWmhVODNGeUxfZ2xJdHFOUlk4RkU1TFJBbjVMQktlRW1Oakw1b1ZmdHloXzRWUzhNS1d0SzE1V0NB?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5LbTJPNGtNNEVzdElUeF8xQmNfaFFqNEJvTWk0TUV4bG5BajdpQTBZaldLZGhycElhQzhIVzZCOG43VmJqMEJUUTk0NG1OY3M?oc=5", "source_name": "CNN", "published_at": "2024-02-07T23:14:34+00:00", "published_display": "07 Feb 2024 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Metagenomi Therapeutics (MGX) Edges Higher as Stock Tests Key Resistance Near $1.41 - Small Cap Breakouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMWRSNGhNeVdsWXJqeE1xdmxVQl9sTjR4ZFVLS3dOR0VwQ1hjLWFGLVRqTzlwRTd4QnNDZlkzaWNjNVhmaWUzcWo3RnlnZ0NhNUktNmR0VS1Gem5SbDVQcnd6TS1aZHN2QkhHR1FlRjRTR3ZNcXd0Qndod2VjX0Zzbl9qUWY1TE5xTklrUUhqWjIzNFVGRkFqWW10REFEeWFJdUduQW5rVjJmRmxZcmU5bk9KUWZzS0swSzRWYkp3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T17:33:34+00:00", "published_display": "14 Jul 2026 17:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential", "summary": "Chardan has initiated coverage on Metagenomi Inc (NASDAQ:MGX) with a buy rating and a $5.00 price target, citing the potential of its lead asset, MGX-001, as a one-time curative treatment for Hemophilia A. The firm believes MGX-001's proprietary gene editing approach is superior ", "url": "https://ng.investing.com/news/stock-market-news/chardan-initiates-metagenomi-stock-with-buy-5-target-on-gene-therapy-potential-93CH-2588641", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T06:40:15", "published_display": "08 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Cuts Price Target on Metagenomi to $5 From $7, Keeps Buy Rating", "summary": "Chardan has revised its price target for Metagenomi (MGX) down to $5 from $7, while maintaining a Buy rating on the stock. This adjustment comes despite the retained positive outlook from the analyst firm. Investors should note this change in valuation target.", "url": "https://www.moomoo.com/news/post/72584690/chardan-cuts-price-target-on-metagenomi-to-5-from-7?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T17:41:34", "published_display": "07 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit", "summary": "Rosen Law Firm reminds investors who purchased Metagenomi, Inc. (NASDAQ: MGX) stock during its IPO between February 9-13, 2024, of the November 25, 2024, lead plaintiff deadline for a class action lawsuit. The lawsuit alleges that Metagenomi misrepresented its relationship with M", "url": "https://www.gurufocus.com/news/2601404/mgx-deadline-mgx-investors-have-opportunity-to-lead-metagenomi-inc-securities-lawsuit?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-06T18:40:19", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Metagenomi Therapeutics, Inc. (MGX) stock, including analyst opinions, historical performance data, and key financial metrics. It highlights that analysts project a maximum price of $9.00 and a minimum of $5.00 for MGX, while ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:49", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "This article focuses on the \"Price to earnings forward\" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It is a financial data point presented within the context of TradingView's platform, indicating a specific financial valuation for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:08", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "The article indicates the \"Price to book forward\" for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It provides basic financial information and market data for the company on TradingView. The content appears to be a stub or a section of a larger financial data page rather than a f", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:18", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Metagenomi Therapeutics, Inc. \u2013 NASDAQ:MGX", "summary": "This article provides the \"Price to sales forward\" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, alongside standard disclaimers from data providers like ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:48", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX)", "summary": "This article provides an overview of Metagenomi Therapeutics, Inc. (NASDAQ: MGX) stock performance, analyst forecasts, and key financial data. It covers the current stock price, historical highs and lows, volatility, earnings per share, revenue, net income, and upcoming earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:27", "published_display": "26 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Inc (MGX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed overview of Metagenomi Inc (MGX) stock, focusing on its dividend and stock split history, which currently shows no data for either. It includes current stock performance metrics such as market cap and price changes. The page also features an overvi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mgx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:29", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares", "summary": "Metagenomi Therapeutics (MGX) director Dere Willard H was granted stock options for 21,000 shares of common stock. The options have an exercise price of $1.23 per share and will expire on June 8, 2036. These options will vest fully on the earlier of one year from the grant date o", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-1ae26ccc5773.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:35", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23", "summary": "Metagenomi Therapeutics (MGX) director Reid Laurence was granted 17,400 stock options with an exercise price of $1.23 per share, expiring on June 8, 2036. These options will vest on the earlier of one year from the grant date or the company\u2019s 2027 annual stockholder meeting, cont", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-c648aa8371f9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:35", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23", "summary": "Metagenomi Therapeutics director Eric Bjerkholt was granted stock options for 21,000 shares of common stock at an exercise price of $1.23 per share. These options will vest and become exercisable on the earlier of one year from the grant date or the company's 2027 annual meeting ", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-3531ad7ada72.html", "source_name": "Stock Titan", "published_at": "2026-06-11T17:49:03", "published_display": "11 Jun 2026 17:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike", "summary": "Metagenomi Therapeutics, Inc. director Juergen Eckhardt was granted 21,000 stock options with an exercise price of $1.23 per share and an expiration date of June 8, 2036. The options will vest either on the one-year anniversary of the grant date or the company's 2027 annual meeti", "url": "https://www.stocktitan.net/sec-filings/MGX/form-4-metagenomi-therapeutics-inc-insider-trading-activity-96abf9892996.html", "source_name": "Stock Titan", "published_at": "2026-06-11T17:38:03", "published_display": "11 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CEO Jian Irish sells $4,854 in company stock", "summary": "Metagenomi's CEO, Jian Irish, sold 3,737 shares of the company's common stock amounting to $4,854. This transaction was an automatic sale to cover tax withholding obligations related to restricted stock units rather than a discretionary trade. Following the sale, Ms. Irish direct", "url": "https://m.uk.investing.com/news/insider-trading-news/metagenomi-ceo-jian-irish-sells-4854-in-company-stock-93CH-4722247?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T19:10:09", "published_display": "10 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CFO Pamela Wapnick sells $3,746 of company stock", "summary": "Metagenomi CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 on June 5, 2026, to satisfy tax withholding obligations related to vested restricted stock units. This was not a volitional trade, and she now directly owns 208,491 shares. The company's s", "url": "https://m.uk.investing.com/news/insider-trading-news/metagenomi-cfo-pamela-wapnick-sells-3746-of-company-stock-93CH-4722234?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-10T19:10:09", "published_display": "10 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com", "summary": "Metagenomi Therapeutics, Inc. CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 due to tax withholding obligations upon the vesting of restricted stock units. This transaction was not a volitional trade. The company's stock, NASDAQ:MGX, is trading n", "url": "https://ng.investing.com/news/insider-trading-news/metagenomi-cfo-pamela-wapnick-sells-3746-of-company-stock-93CH-2552402", "source_name": "Investing.com Nigeria", "published_at": "2026-06-10T18:11:03", "published_display": "10 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi CEO Jian Irish sells $4,854 in company stock By Investing.com", "summary": "Metagenomi CEO Jian Irish sold 3,737 shares of Metagenomi Therapeutics (NASDAQ:MGX) common stock for $4,854 to cover tax withholding obligations related to restricted stock units. This was an automatic, non-discretionary transaction. Following the sale, Ms. Irish directly holds 3", "url": "https://au.investing.com/news/insider-trading-news/metagenomi-ceo-jian-irish-sells-4854-in-company-stock-93CH-4480994", "source_name": "Investing.com Australia", "published_at": "2026-06-10T17:30:39", "published_display": "10 Jun 2026 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVTS Stock Surges as NVIDIA MGX Tests Revenue Reality", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1lVmJwRlFsT2Z2TmdEYUxjVThfMHpmekxyaE5ZZmlBc2RQbFFkRXIzRmd4WVVNSS1lM01NOWE3Qzl4NG1jR0lkVmp3MnF4bTlJYkliSEZjNExSUklhb2pydjYydU5USzdfU3poYllaZUJSZw?oc=5", "source_name": "EBC Financial Group", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rainmaker NVIDIA has another AI Infrastructure Stock (NASDAQ:NVTS) Soar on News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNb1RMUEpfVUI0eEJoTzhkajgxMW96LW40YTNETVhNWG1uUXh3SUxoTExIM0JhZ1FCRGNDMjd3azlzeU43a2Q0SnNmOUUxR1lONHBfYWdYTHgwenlzdy1uX0NOdEY0OTNHQV9STEw3QVp5QzRYV1FYWWd0b3pFNVNHOGhlZ1MxZ29PdnFjd25ObFp3SVV2LWx0NklIMGhGOWl0S21EbzZSczA?oc=5", "source_name": "Investorideas.com", "published_at": "2026-06-03T16:59:00+00:00", "published_display": "03 Jun 2026 16:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVTS stock surges on NVIDIA MGX collaboration for 800V AI infrastructure", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQM2d4NUVvWWNfWTdZQS0xWkVCdTJRLWZnT0lnMGFwTnRudUUzdkY3YzAxbElzSUV3cTI4SVlyV3dUWmgxaEJ5R3U4NjJOT1dqel9RbHItNUlhWGJHeEwxT3RDcklIeHc1NkNfY0NjVDlfYnlEa2swRXVNRXE5VkdrTWtZbXE5RlRGLU5YTTFPSDdXTlAxcXlDd2ptclhkLUlhazdJ?oc=5", "source_name": "eciks.org", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Navitas Stock Surges 23% on Nvidia AI Partnership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNYW9pRTdwMXN3bHdNR1ZWSDdGWXBJN1FzMUExM2JOS0RQT1UxMWFQYm92Nk9uUENIUXVSMjEydWh2OVc2NFctelVKa3VNLVVwRGwxVkMweXFyU0hTalVrakVMYlpLSzFTZnN3WmpPMGNCYmx0WjJMOXl4cmVUUXQ4aG52Z0JjV1NuZVE?oc=5", "source_name": "Barron's", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia MGX news makes Navitas stock more expensive than SpaceX at $1.7 trillion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaGY5Z2RjeTJXNUw1SXpoWW41ZHZCUjBpUWUwaUFra2lLSXU1SmZTQ3oyZ29xY3Vmb3E2d09NZjBjNU5femNSUEhtZWRaZEZWcE02M1hFNE1Zd2F6bmFJdnJyRHF4SXdCamFKak5malh5WHpzQkdlRmtHUk5iaDZWSkdKczNPUk51VDluSDdQLVNKWk9nOWhvZ2tkcXlJVF93cTJuYXQtbnczUQ?oc=5", "source_name": "Invezz", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPVVJkV0pacXBoUkV0eTdLcWlJcUhFR2ZDODg0VkR6RWQtajJhRmdTVEpyWU1SMlpaSXJMb2RXSmZvamx5al9RcWhwSVRBREhYbHc1ajFqQ0Q1UWdXemhsa1JMTUFpdUV1Z1RvOHRNNlNWVTRsLTktZUtSY190NjJ5dExISUpCM25aV2xweW1lSGlSUUlMMUtla3U3VzRiaTNvYURTaVpR?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNNjl2Ym1UWGZIV2EyeVVrMnotQXd6WHF3Z2t0UURBdm1LWUNNcDdoMHFMNS1QQUxrTlNxVWFtdmlFSVZaTTNCQkNjUC1BOHNzUlNYZzJIZ3ZmYURyb1ZVOGNHVERJREdjV3lySThnT084ZUhoVnNJdzhkTS1RUWF1S1E0ZEVkZzBVN3lpeEV3?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle stock jumps 7% as cloud provider joins investor group to run TikTok's U.S. business", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE83a0c4UkFnOHpsTzRRdkZ5OFA0RDZtVC0yNUpHbEtJMzVFclg3Q2V3bk9sS1dzbXhCeHFHdkxwZHJTSDJJSUx4ckxGSlVjR1I1U2NKY0dmTkhmem5nX3lmaHRZTW16dDloWHNxNU9jZWRDZGY5ZUd5d1ZOMNIBgAFBVV95cUxNQnhyekllQ3ZjbE5kYmRVODctb1ZBeXphV21YTDYtTzhZTmloTzc1UGdaYlhvVWFraEU1RjFJcEZsWVFyRlliYVhkbmRwOUxkVzJxRmNhU2d1X0Zrblpad3BTRWRrekUwZ0tRZWszcUdZQVdmMXFzdzFFRk5TcHhXOQ?oc=5", "source_name": "CNBC", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oracle Stock Jumps After Forming TikTok Joint Venture", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYnhKQTJmc19GNmdVNlF0VjdmMkZ6S21mQ2l0cExGRmN2Y0ZQR2F5d040UjhSRW5QTVl0TmlCbzBUanRuSW11Tjk2czZqVy1ldEFPWlRhdS1ZS0FINFJXWlUwU1JKNUg4RDJFQngya1pxbDVBNVl0X29lanlDb1VVb2V4UGgwZDJS?oc=5", "source_name": "Barron's", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNWWdIaG8zemNob2FuRVhJMG9sWVpMSl9NbkdyMVVpOXUtR0NJS2ZrTDFmc3RldHZaOURUU0VfNG1jeEtmeXdjSVhHWmhVODNGeUxfZ2xJdHFOUlk4RkU1TFJBbjVMQktlRW1Oakw1b1ZmdHloXzRWUzhNS1d0SzE1V0NB?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5LbTJPNGtNNEVzdElUeF8xQmNfaFFqNEJvTWk0TUV4bG5BajdpQTBZaldLZGhycElhQzhIVzZCOG43VmJqMEJUUTk0NG1OY3M?oc=5", "source_name": "CNN", "published_at": "2024-02-07T23:14:34+00:00", "published_display": "07 Feb 2024 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 50, "sentiment_summary": {"positive": 13, "negative": 6, "neutral": 31, "score": 53, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.8, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.9, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 1.24, "latest_week": "2026-07-17", "one_week_move": -2.4, "four_week_move": 3.3, "twelve_week_move": -17.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.274564, "market_dynamics_buy_signal": false, "relative_strength": -36.133579, "fair_value_gap": -60.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.4603, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.4% over one week, +3.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "Barron's", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "eciks.org", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.4% over one week, +3.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Metagenomi Therapeutics (MGX) Edges Higher as Stock Tests Key Resistance Near $1.41 - Small Cap Breakouts"}], "updated_at": "2026-07-23T00:57:25.671632+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}